S2-E24.1 – From the Fourth Global NASH Congress — Changing Paradigms and Guidelines

After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to conisder key takeaways from the Congress. This conversation is organized around changes in treatment paradigms and guidelines.

After hearing presentations from 43 speakers at the Fourth Global NASH Congress, the Surfing the NASH Tsunami team convenes one more time to consider how treatment paradigms and guidelines are likely to evolve over the next five years. This discussion focuses on general themes and differences between the US and UK market evolution. The conversation includes controversy and probing questions, all with laughter and camaraderie.

TOPICS: Diagnostics, Drugs, Patients, Policy and Perspectives Tags: aldafermin, cirrhosis, FGF-21, FibroScan, Fibrosis Level 3, Fibrosis Level 4, Genfit, NAFLD, NASH, NGM Biopharmaceuticals, Precision medicine, NICE, cost-effectiveness, guidelines, PMPLA3, resmetirom

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Request A Transcript of This Episode
Request Transcript
First
Last

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"